Gilead's remdesivir prevents Covid-19 progression

Gilead Sciences Update On The Company’s Ongoing Response To COVID-19

Gilead is working closely with global health authorities to respond to the novel coronavirus (COVID-19) outbreak through the appropriate experimental use of the investigational compound remdesivir. Together with the U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS), National Institute of Allergies and Infectious Diseases (NIAID) and Department of Defense (DoD) - CBRN Medical; the China CDC and National Medical Product Administration (NMPA); the World Health Organization (WHO); and researchers and clinicians across Europe and Asia; Gilead is focused on contributing our antiviral expertise and resources to help patients and communities fighting COVID-19.

Gilead's Remdesivir Shows Promise Against COVID-19 in Sneak Peek at Clinical Trial Data


NASDAQ: GILD

Comments